HYDRODIURIL (nda011835)- (25MG,50MG,100MG)

Generic Name	HYDROCHLOROTHIAZIDE	Innovator	MERCK
Dosage	25MG,50MG,100MG
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	Expired	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	Hydrochlorothiazide tablets, USP are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets, USP have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets, USP are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
11	0	11

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	Yes

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
25MG	**	**	-	-	8
50MG	**	**	-	-	8
100MG	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	9

Manufacturing Details of HYDRODIURIL